Show simple item record

dc.contributor.authorTsilingiri, Katerina 
dc.contributor.authorFornasa, Giulia
dc.contributor.authorRescigno, Maria
dc.identifier.citationCell Mol Gastroenterol Hepatol. 2017; 3(2):174-182es_ES
dc.description.abstractThymic stromal lymphopoietin (TSLP) was identified more than 20 years ago as a secreted factor of a mouse thymic stromal cell line; later, a human orthologue was also identified. The signaling pathway triggered by TSLP has been extensively studied, and upregulation of the cytokine itself is linked to the pathogenesis of numerous Th2-related diseases, including atopic dermatitis, asthma, allergic responses, as well as certain types of cancers. On the other hand, TSLP mediates several immune homeostatic functions in both the gut and the thymus. Thus, a paradox occurs; why is TSLP homeostatic in certain tissues and a hallmark of exacerbated Th2 responses in the aforementioned pathologies? We and others have recently shown that in humans a novel isoform exists; this is a shorter isoform of TSLP whose expression is constitutive and controlled by a separate promoter. Short TSLP isoform mediates the homeostatic functions, whereas the long isoform is expressed at low/undetectable level at steady state and upregulated during inflammation in several tissues. Here we review the most recent data concerning the differential expression of the 2 isoforms and provide a potential explanation to the paradox. TSLP is regarded as a promising target for treatment of relevant pathologies, with a number of clinical trials already underway. It is important to design new strategies aimed at leaving intact the homeostatic effects of the short isoform while targeting the inflammatory effects of the long isoform.es_ES
dc.subjectAtopic Diseaseses_ES
dc.subjectDC, dendritic celles_ES
dc.subjectGut Homeostasises_ES
dc.subjectIFN, interferones_ES
dc.subjectIL, interleukines_ES
dc.subjectILC, innate lymphoid cellses_ES
dc.subjectMAPK, mitogen-activated protein kinasees_ES
dc.subjectNF-κB, nuclear factor kappa Bes_ES
dc.subjectTLR, toll-like receptores_ES
dc.subjectTNF, tumor necrosis factores_ES
dc.subjectTSLP, thymic stromal lymphopoietines_ES
dc.subjectTSLPR, thymic stromal lymphopoietin protein receptores_ES
dc.subjectTherapeutic Targetses_ES
dc.subjectThymic Stromal Lymphopoietines_ES
dc.subjectTreg, regulatory T cellses_ES
dc.titleThymic Stromal Lymphopoietin: To Cut a Long Story Shortes_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.journalCellular and molecular gastroenterology and hepatologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Moléculas Reguladoras de los Procesos Inflamatorioses_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional